<![CDATA[Recovery of cone-mediated vision in teenagers with LCA]]>
In early October, Opus Genetics announced the positive 3-month paediatric data from its phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5), an …